

## Sagent - Recall of docetaxel injection

- On May 29, 2024, the <u>FDA announced</u> a user-level recall of two lots of <u>Sagent Pharmaceutical's</u> <u>docetaxel</u> injection because of a customer complaint due to potential presence of particulate matter from the stopper in the drug product.
- The recalled products were distributed nationwide from October 11, 2023 to April 11, 2024.

Product Description	NDC number	Lot number (Exp Date)
Docetaxel injection 160 mg/16 mL (10 mg/mL)	25021-254-16	F1030001 (12/2024)
Docetaxel injection 80 mg/8 mL (10 mg/mL)	25021-254-08	F1040001 (12/2024)

- Docetaxel is indicated for the treatment of breast cancer, non-small cell lung cancer, prostate cancer, gastric adenocarcinoma, and head and neck cancer.
- Intravenous administration of an injectable product that contains particulate matter may result in serious adverse events. Potential complications related to injection of particles include inflammation of a vein, granuloma, and blockage of blood vessels in the heart, lungs or brain which can cause stroke or life-threatening blood clot events.
- The frequency and severity of these adverse events could vary depending upon a variety of factors including the size and number of particles in the drug product, patient comorbidities (such as age, compromised organ function), and presence or absence of vascular anomalies.
- To date, Sagent Pharmaceuticals has not received any reports of adverse events related to this
  recall.
- Anyone with an existing inventory of the product being recalled should discontinue use, stop distribution, and return recalled product.
- Contact Sagent customer call center at **1-866-625-1618**, **option 1** for questions regarding this recall. Healthcare workers with questions about the recall may contact Sagent Medical Affairs at **1-866-625-1618**, **option 3**.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews® is published by the Optum Rx Clinical Services Department.